News & Updates

Show Multimedia Only

OS data show promise for risvutatug rezetecan in R/R sarcoma

22 Jul 2026 by

Longer-term follow-up of the phase II ARTEMIS-002 trial continues to show promising efficacy of risvutatug rezetecan (ris-rez) in relapsed or refractory (R/R) sarcoma, with median overall survival (OS) reaching about 2 years, according to data presented at ESMO TAT Asia 2026.

OS data show promise for risvutatug rezetecan in R/R sarcoma

22 Jul 2026

Post-MI beta-blocker use lowers mortality risk in COPD patients

22 Jul 2026

Beta-blocker therapy following myocardial infarction (MI) reduces the risk of death in patients with comorbid chronic obstructive pulmonary disease (COPD), with the magnitude of benefit similar to that observed in patients without COPD, according to a Danish cohort study.

Post-MI beta-blocker use lowers mortality risk in COPD patients

22 Jul 2026

Vedolizumab induces clinical remission in paediatric patients with UC

22 Jul 2026 by

Treatment with either low- or high-dose vedolizumab yields high rates of clinical remission in children with moderate-to-severe ulcerative colitis (UC), regardless of weight, according to the phase III KEPLER trial presented at ESPGHAN 2026.

Vedolizumab induces clinical remission in paediatric patients with UC

22 Jul 2026

Hydroxychloroquine does little to prevent recurrent miscarriage

20 Jul 2026

Treatment with hydroxychloroquine does not appear to improve the chances of livebirth for women with a history of three consecutive miscarriages, according to a phase III study.

Hydroxychloroquine does little to prevent recurrent miscarriage

20 Jul 2026

Upadacitinib tied to better survival vs tofacitinib in MDA5+DM-ILD

20 Jul 2026

Upadacitinib demonstrates its noninferiority to tofacitinib in improving lung transplantation-free survival (LTFS) at 6 months among patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD), reports a study.

Upadacitinib tied to better survival vs tofacitinib in MDA5+DM-ILD

20 Jul 2026

Statins may protect against site-specific cancers

20 Jul 2026

Statin use may reduce the risk of cancer at several sites, including the liver, lung, colon, and rectum, especially for individuals with diabetes, as shown in a retrospective study.

Statins may protect against site-specific cancers

20 Jul 2026

$Maintenance upadacitinib efficacious in refractory paediatric UC$

Maintenance upadacitinib efficacious in refractory paediatric UC

19 Jul 2026 by

Maintenance treatment with upadacitinib helps sustain remission in children with refractory ulcerative colitis (UC), according to a retrospective study.

Maintenance upadacitinib efficacious in refractory paediatric UC

19 Jul 2026

Stopping anti-TNF therapy risky in paediatric IBD

18 Jul 2026 by

Paediatric inflammatory bowel disease (IBD) patients who have achieved clinical remission on tumour necrosis factor inhibitor (anti-TNF) therapy are likely to flare if they stop treatment, researchers from the IBD Porto Group of ESPGHAN have found.

Stopping anti-TNF therapy risky in paediatric IBD

18 Jul 2026

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026 by

Nearly a third of glioblastoma patients treated with standard radiotherapy plus temozolomide (STUPP protocol) suffer early-onset radiation induced leukoencephalopathy (RIL), which is linked to early cognitive and functional decline, according to a study.

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

17 Jul 2026

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026 by

The investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib demonstrates its noninferiority to ocrelizumab in reducing the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS) in the phase III FENtrepid study.

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

17 Jul 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

OS data show promise for risvutatug rezetecan in R/R sarcoma

OS data show promise for risvutatug rezetecan in R/R sarcoma

Post-MI beta-blocker use lowers mortality risk in COPD patients

Post-MI beta-blocker use lowers mortality risk in COPD patients

Vedolizumab induces clinical remission in paediatric patients with UC

Vedolizumab induces clinical remission in paediatric patients with UC

Hydroxychloroquine does little to prevent recurrent miscarriage

Hydroxychloroquine does little to prevent recurrent miscarriage

Upadacitinib tied to better survival vs tofacitinib in MDA5+DM-ILD

Upadacitinib tied to better survival vs tofacitinib in MDA5+DM-ILD

Statins may protect against site-specific cancers

Statins may protect against site-specific cancers

Maintenance upadacitinib efficacious in refractory paediatric UC

Maintenance upadacitinib efficacious in refractory paediatric UC

Stopping anti-TNF therapy risky in paediatric IBD

Stopping anti-TNF therapy risky in paediatric IBD

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

Early-onset RIL in glioblastoma patients treated with STUPP warrants monitoring

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS

Novel BTK inhibitor on par with ocrelizumab in reducing disability progression in PPMS